Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Stock Information for MicroVision Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MicroVision Inc.

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now
Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
Bioxytran's Medical Breakthrough in Fighting All Viruses
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Bioxytran's Advisor Releases Book on Hyperbaric Oxygenation Related to Stroke & Alzheimer's Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.